Beyond Air (NASDAQ:XAIR) Announces Earnings Results, Misses Estimates By $0.45 EPS

Beyond Air (NASDAQ:XAIR) posted its quarterly earnings data on Wednesday. The company reported ($3.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.31) by ($0.45), Zacks reports. Beyond Air had a negative return on equity of 440.26% and a negative net margin of 435.71%.

Beyond Air Stock Up 4.4%

NASDAQ:XAIR traded up $0.11 during trading hours on Wednesday, hitting $2.63. 626,930 shares of the stock traded hands, compared to its average volume of 182,259. The firm has a 50 day moving average price of $2.68 and a 200 day moving average price of $9.55. The company has a current ratio of 3.31, a quick ratio of 3.12 and a debt-to-equity ratio of 7.81. Beyond Air has a fifty-two week low of $2.05 and a fifty-two week high of $53.20. The firm has a market cap of $2.52 million, a price-to-earnings ratio of -0.04 and a beta of 0.23.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Lake Street Capital began coverage on shares of Beyond Air in a report on Tuesday, September 1st. They issued a “buy” rating and a $10.00 target price for the company. Weiss Ratings raised shares of Beyond Air from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, October 29th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $105.00.

Beyond Air Company Profile

Beyond Air, Inc. is a medical technology and biopharmaceutical company focused on developing nitric oxide (NO) therapies and delivery systems for respiratory diseases and other serious medical conditions. Its platform is designed to generate NO from ambient air at the point of care, potentially reducing reliance on traditional high-pressure gas cylinders. The company’s primary product family is LungFit, a series of compact NO delivery systems intended for use in hospital and clinical settings. LungFit PH is designed to deliver inhaled nitric oxide to term and near-term neonates with hypoxic respiratory failure associated with pulmonary hypertension.